Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-0416 SAD and MAD in Healthy Participants
NCT07724431Phase 1Not yet recruiting
- Sponsor
- Curegene Innovation
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CG-0416 in obesity and Overweight (8 cohorts), sponsored by Curegene Innovation. Primary endpoints: Number of participants with treatment-related adverse events up to 3 weeks and Safety and tolerability of single and multiple doses up to 3 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CG-0416
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07724431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724431.